Logo image of XRTX

XORTX THERAPEUTICS INC (XRTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XRTX - CA98420Q3061 - Common Stock

0.562 USD
+0 (+0.36%)
Last: 12/31/2025, 8:00:02 PM
0.5151 USD
-0.05 (-8.35%)
After Hours: 12/31/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, XRTX scores 1 out of 10 in our fundamental rating. XRTX was compared to 191 industry peers in the Pharmaceuticals industry. XRTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. XRTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XRTX has reported negative net income.
In the past year XRTX has reported a negative cash flow from operations.
In the past 5 years XRTX always reported negative net income.
XRTX had a negative operating cash flow in each of the past 5 years.
XRTX Yearly Net Income VS EBIT VS OCF VS FCFXRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

XRTX's Return On Assets of -69.13% is on the low side compared to the rest of the industry. XRTX is outperformed by 70.68% of its industry peers.
XRTX has a worse Return On Equity (-98.46%) than 63.35% of its industry peers.
Industry RankSector Rank
ROA -69.13%
ROE -98.46%
ROIC N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
XRTX Yearly ROA, ROE, ROICXRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XRTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XRTX Yearly Profit, Operating, Gross MarginsXRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

XRTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, XRTX has less shares outstanding
XRTX has a worse debt/assets ratio than last year.
XRTX Yearly Shares OutstandingXRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
XRTX Yearly Total Debt VS Total AssetsXRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -9.49, we must say that XRTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.49, XRTX is doing worse than 70.68% of the companies in the same industry.
There is no outstanding debt for XRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.49
ROIC/WACCN/A
WACCN/A
XRTX Yearly LT Debt VS Equity VS FCFXRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 1.62 indicates that XRTX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.62, XRTX is doing worse than 69.11% of the companies in the same industry.
A Quick Ratio of 1.62 indicates that XRTX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.62, XRTX is in line with its industry, outperforming 40.31% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.62
XRTX Yearly Current Assets VS Current LiabilitesXRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for XRTX have decreased strongly by -1213.33% in the last year.
EPS 1Y (TTM)-1213.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XRTX Yearly EPS VS EstimatesXRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XRTX Price Earnings VS Forward Price EarningsXRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XRTX Per share dataXRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

XRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

XORTX THERAPEUTICS INC

NASDAQ:XRTX (12/31/2025, 8:00:02 PM)

After market: 0.5151 -0.05 (-8.35%)

0.562

+0 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2025-11-14
Earnings (Next)03-30 2026-03-30/amc
Inst Owners1.45%
Inst Owner Change53.55%
Ins Owners1.87%
Ins Owner ChangeN/A
Market Cap3.91M
Revenue(TTM)N/A
Net Income(TTM)-1.94M
Analysts80
Price TargetN/A
Short Float %0.57%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.98
P/tB 2.2
EV/EBITDA N/A
EPS(TTM)-0.47
EYN/A
EPS(NY)-1.55
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS0.28
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.13%
ROE -98.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.62
Quick Ratio 1.62
Altman-Z -9.49
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)48.3%
Cap/Depr(5y)87.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1213.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.88%
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.46%
OCF growth 3YN/A
OCF growth 5YN/A

XORTX THERAPEUTICS INC / XRTX FAQ

What is the ChartMill fundamental rating of XORTX THERAPEUTICS INC (XRTX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to XRTX.


What is the valuation status of XORTX THERAPEUTICS INC (XRTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to XORTX THERAPEUTICS INC (XRTX). This can be considered as Overvalued.


Can you provide the profitability details for XORTX THERAPEUTICS INC?

XORTX THERAPEUTICS INC (XRTX) has a profitability rating of 0 / 10.


What is the financial health of XORTX THERAPEUTICS INC (XRTX) stock?

The financial health rating of XORTX THERAPEUTICS INC (XRTX) is 5 / 10.


What is the earnings growth outlook for XORTX THERAPEUTICS INC?

The Earnings per Share (EPS) of XORTX THERAPEUTICS INC (XRTX) is expected to decline by -11.64% in the next year.